Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudin's plasma halflife.
Huhle
G
G
Liebe
V
V
Hudek
R
R
Heene
D L
DL
D000368:Aged; D000911:Antibodies, Monoclonal / Q000097:blood* / Q000494:pharmacology / Q000627:therapeutic use; D000915:Antibody Affinity; D000991:Antithrombins / Q000008:administration & dosage / Q000276:immunology* / Q000493:pharmacokinetics; D005260:Female; D006207:Half-Life; D024764:Hirudin Therapy; D006629:Hirudins / Q000008:administration & dosage / Q000276:immunology* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000493:pharmacokinetics; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D000991:Antithrombins; D006629:Hirudins; D011994:Recombinant Proteins